| PMID |
16909005 ( ![]() ![]() ![]() ) |
|---|---|
| Title | Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. |
| Abstract | There is substantial evidence that both inflammation and oxidative damage contribute to the pathogenesis of motor neuron degeneration in the G93A SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS). Celastrol is a natural product from Southern China, which exerts potent anti-inflammatory and antioxidative effects. It also acts potently to increase expression of heat shock proteins including HSP70. We administered it in the diet to G93A SOD1 mice starting at 30 days of age. Celastrol treatment significantly improved weight loss, motor performance and delayed the onset of ALS. Survival of celastrol-treated G93A mice increased by 9.4% and 13% for 2 mg/kg/day and 8 mg/kg/day doses, respectively. Cell counts of lumbar spinal cord neurons confirmed a protective effect, i.e. 30% increase in neuronal number in the lumbar spinal cords of celastrol-treated animals. Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice. TNF-alpha immunoreactivity co-localized with SMI-32 (neuronal marker) and GFAP (astrocyte marker). HSP70 immunoreactivity was increased in lumbar spinal cord neurons of celastrol-treated G93A mice. Celastrol has been widely used in treating inflammatory diseases in man, and is well tolerated; therefore, it may be a promising therapeutic candidate for the treatment of human ALS. University, New York-Presbyterian Hospital, New York, NY 10021, USA. mak2026@med.cornell.edu |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | 4 | TNF-alpha | tnf alpha | |
| 5232 | HSPA1A | heat shock 70kDa protein 1A | 3 | hsp70 | HSP70 | |
| 4235 | GFAP | glial fibrillary acidic protein | 2 | GFAP | |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | 2 | SOD1 | |
| 7873 | NOS2A | nitric oxide synthase 2A (inducible, hepatocytes) | 1 | iNOS | |
| 11919 | CD40 | CD40 molecule, TNF receptor superfamily member 5 | 1 | CD40 | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 1.7 | to the pathogenesis of motor neuron degeneration in the G93A SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS) ALS |
| 5232 | HSPA1A | heat shock 70kDa protein 1A | HSP70 | 1.2 | acts potently to increase expression of heat shock proteins including HSP70 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 1.7 | We administered it in the diet to G93A SOD1 mice starting at 30 days of age |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 2.7 | Celastrol treatment reduced TNF-alpha iNOS CD40 and GFAP immunoreactivity in the lumbar spinal cord |
| 7873 | NOS2A | nitric oxide synthase 2A (inducible, hepatocytes) | iNOS | 1.0 | Celastrol treatment reduced TNF-alpha iNOS CD40 and GFAP immunoreactivity in the lumbar spinal cord sections |
| 11919 | CD40 | CD40 molecule, TNF receptor superfamily member 5 | CD40 | 0.6 | Celastrol treatment reduced TNF-alpha iNOS CD40 and GFAP immunoreactivity in the lumbar spinal cord sections of |
| 4235 | GFAP | glial fibrillary acidic protein | GFAP | 2.5 | Celastrol treatment reduced TNF-alpha iNOS CD40 and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 2.7 | TNF-alpha immunoreactivity co-localized with SMI-32 (neuronal neuronal marker and GFAP (astrocyte |
| 4235 | GFAP | glial fibrillary acidic protein | GFAP | 2.5 | TNF-alpha immunoreactivity co-localized with SMI-32 (neuronal neuronal marker and GFAP (astrocyte astrocyte marker |
| 5232 | HSPA1A | heat shock 70kDa protein 1A | HSP70 | 1.2 | HSP70 immunoreactivity was increased in lumbar spinal cord neurons of celastrol-treated |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | celastrol treatment reduced tnf alpha inos cd40 and gfap immunoreactivity in the lumbar spinal cord sections of celastrol treated g93a mice compared to untreated g93a mice. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | tnf alpha immunoreactivity co localized with smi 32 neuronal marker and gfap astrocyte marker . |
| 5232 | HSPA1A | heat shock 70kDa protein 1A | hsp70 | 1.0 | hsp70 immunoreactivity was increased in lumbar spinal cord neurons of celastrol treated g93a mice. |